TY - JOUR
T1 - Pathophysiology, prevention, and treatment of medication overuse headache
AU - Diener, Hans Christoph
AU - Dodick, D.
AU - Evers, Stefan
AU - Holle, D.
AU - Jensen, Rigmor Hoejland
AU - Lipton, Richard B.
AU - Porreca, F.
AU - Silberstein, Stephen
AU - Schwedt, Todd
N1 - Funding Information:
HCD received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Alder, Allergan, Amgen, Autonomic Technology, Bristol-Myers Squibb, CoLucid, Electrocore, Ipsen, Lilly, Medtronic, Merck Sharp & Dohme, Novartis, Pfizer, Schaper and Brümmer, Teva, and Weber & Weber; financial support for research projects was provided by Allergan, Electrocore, Merck Sharp & Dohme, and Pfizer; headache research at the Department of Neurology in Essen is supported by the German Research Council, the German Ministry of Education and Research, and the EU; has no ownership interest and does not own stocks of any pharmaceutical company; serves on the editorial boards of Cephalalgia and The Lancet Neurology; chairs the Clinical Guidelines Committee of the German Society of Neurology; and is member of the Clinical Trials Committee of the International Headache Society. DD reports personal fees from Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck Sharp & Dohme, NuPathe, Eli Lilly and Company, Autonomic Technologies, Ethicon J&J, Zogenix, Supernus, Labrys, Boston Scientific, Medtronic, St Jude, Bristol-Myers Squibb, Lundbeck, Impax, MAP, electroCore, Tonix, Novartis, Teva, Alcobra, Zosano, ZP Opco, Insys, Ispen, Acorda, eNeura, Charleston Laboratories, Gore, Biohaven, Biocentric, Magellan, Theranica, Xenon, Dr Reddy's/Promius Pharma, Vedanta, CC Ford West Group, Foresight, Satsuma, Axsome, Impel, Neurolief, IntraMed, SAGE Publishing, Sun Pharma, Oxford University Press, American Academy of Neurology, American Headache Society, West Virginia University Foundation, Canadian Headache Society, Healthlogix, Universal Meeting Management, WebMD, UptoDate, Medscape/WebMD, Oregon Health Science Center, Albert Einstein University, University of Toronto, Starr Clinical, Decision Resources, Synergy, MedNet LLC, Peer View Institute for Medical Education, Medicom, Medlogix, Wolters Kluwer Health, Chameleon Communications, Academy for Continued Healthcare Learning, Haymarket Medical Education, Global Scientific Communications, Miller Medical, MeetingLogiX, Wiley Blackwell; other support from Dr Reddy's/Promius Pharma, Epien, GBS/Nocira, Second Opinion, Healint, NeuroAssessment Systems, Myndshft; holds equity (stock options) in Aural Analytics, Theranica, Healint, King Devick Technologies, Ontologics/Matterhorn, Nocira, Second Opinion, Aural Analytics, and Epien; is on the board of directors of King-Devick Technologies and Ontologics/Matterhorn, Aural Analytics, and Epien, outside the submitted work; and has a patent (number 17189376·1–1466:v; Botulinum toxin dosage regimen for chronic migraine prophylaxis). SE has received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Allergan, Johnson & Johnson, Lilly, Novartis, Reckitt Benckiser, and Teva; has no ownership interest and does not own stocks of any pharmaceutical company; serves on the editorial boards of Cephalalgia and European Journal of Pain; and is Honorary Secretary of the International Headache Society and Chair of the Headache Panel of the European Academy of Neurology. DH received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Alder, Allergan, Amgen, Autonomic Technology, Hormosan, Lilly, MSD, Novartis, and Teva; financial support for research projects provided by Allergan and Novartis; headache research at the Department of Neurology in Essen is supported by the German Research Council, the German Ministry of Education and Research, and the EU; and has no ownership interest and does not own stocks of any pharmaceutical company. RHJ has received honoraria, travel grants, and an unrestricted research grant from Autonomic Technologies, Allergan, and Novartis; conducted clinical trials for Eli Lilly, ElectroCore, and ATI; and is director in Lifting The Burden and trustee in International Headache Society. FP has received compensation for consulting from Amgen and Voyager; has stock options in BlackThorn and is an equity partner in Catalina Pharmaceuticals; has received research support from Teva, Ipsen, Lilly, Proximagen, Nektar, Hoba, Voyager, PeptideLogic, the US Department of Defense, the National Institutes of Health (NIH), and the Mayo Clinic; and serves on the Editorial Boards of Cephalalgia and Pain. RBL has received personal fees from Alder, Allergan, Amgen, Electrocore, eNeura, Boston Scientific, Bristol Meyers Squibb, Dr. Reddys, Eli Lilly, Teva, and Vedanta; has also received grant funding from Alder, Electrocore, Novartis, the Migraine Research Fund, the National Headache Foundation, and the NIH; and owns stock in eNeura and Biohaven. SS as served as a consultant or advisory panel member, and receives or has received honoraria from Abide Therapeutics, Alder Biopharmaceuticals, Allergan, Amgen, Avanir Pharmaceuticals, Biohaven Pharmaceuticals, Cefaly, Curelator, Dr. Reddy's Laboratories, Egalet Corporation, GlaxoSmithKline Consumer Health Holdings, eNeura, electroCore Medical, Lilly USA, Medscape, National Institute of Neurological Disorders and Stroke, Satsuma Pharmaceuticals, Supernus Pharmaceuticals, Teva Pharmaceuticals, Theranica, and Trigemina. TJS has received compensation for consulting from Alder, Allergan, Amgen, ATI, Cipla, Ipsen Bioscience, Lilly, Nocira, Novartis, Promius, and Teva; has stock options in Aural Analytics, Nocira, and Second Opinion; has received royalties from Cambridge University Press and Up To Date; has received research funding support from Amgen, Arizona State University, Mayo Clinic, NIH, Patient Centered Outcomes Research Institute, US Department of Defense; serves on the editorial boards of Cephalalgia, Cephalalgia Reports, Headache, and Pain Medicine; and is on the Board of Directors for American Headache Society, American Migraine Foundation, and International Headache Society. All other authors have nothing to declare.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/9
Y1 - 2019/9
N2 - Regular or frequent use of analgesics and acute antimigraine drugs can increase the frequency of headache, and induce the transition from episodic to chronic headache or medication overuse headache. The 1-year prevalence of this condition in the general population is between 1% and 2%. Medication overuse headache is more common in women and in people with comorbid depression, anxiety, and other chronic pain conditions. Treatment of medication overuse headache has three components. First, patients need education and counselling to reduce the intake of medication for acute headache attacks. Second, some patients benefit from drug withdrawal (discontinuation of the overused medication). Finally, preventive drug therapy and non-medical prevention might be necessary in patients at onset of treatment or in patients who do not respond to the first two steps. The optimal therapeutic approach requires validation in controlled trials.
AB - Regular or frequent use of analgesics and acute antimigraine drugs can increase the frequency of headache, and induce the transition from episodic to chronic headache or medication overuse headache. The 1-year prevalence of this condition in the general population is between 1% and 2%. Medication overuse headache is more common in women and in people with comorbid depression, anxiety, and other chronic pain conditions. Treatment of medication overuse headache has three components. First, patients need education and counselling to reduce the intake of medication for acute headache attacks. Second, some patients benefit from drug withdrawal (discontinuation of the overused medication). Finally, preventive drug therapy and non-medical prevention might be necessary in patients at onset of treatment or in patients who do not respond to the first two steps. The optimal therapeutic approach requires validation in controlled trials.
UR - http://www.scopus.com/inward/record.url?scp=85071349577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071349577&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(19)30146-2
DO - 10.1016/S1474-4422(19)30146-2
M3 - Review article
C2 - 31174999
AN - SCOPUS:85071349577
SN - 1474-4422
VL - 18
SP - 891
EP - 902
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 9
ER -